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Members of the protein kinase C (PKC) family of serine-thre-
onine kinases are important regulators of immune cell survival.
Ingenol 3-angelate (PEP005) activates a broad range of PKC iso-
forms and induces apoptosis in acute myeloid leukemia cells by
activating the PKC isoform PKC. We show here that, in con-
trast to its effect on leukemic cells, PEP005 provides a strong
survival signal to resting and activated human T cells. The anti-
apoptotic effect depends upon the activation of PKC. This PKC
isoform is expressed in T cells but is absent in myeloid cells.
Further studies of the mechanism involved in this process
showed that PEP005 inhibited activated CD8 T cell apoptosis
through the activation ofNFBdownstreamofPKC, leading to
increased expression of the antiapoptotic proteins Mcl-1 and
Bcl-xL. Transfection of CD8 T cells with dominant-negative
PKC diminished the prosurvival effect of PEP005 significantly.
Ectopic expression of PKC in the acute myeloid leukemia cell
line NB4 turned their response to PEP005 from an increased to
decreased rate of apoptosis. Therefore, in contrast to myeloid
leukemia cells, PEP005 provides a strong survival signal to T
cells, and the expression of functional PKC influences whether
PKC activation leads to an anti- or proapoptotic outcome in the
cell types tested.
Many cellular processes, including proliferation, differentia-
tion, and apoptosis, are regulated by serine-threonine protein
kinases belonging to the PKC2 isoenzyme family. Due to their
structural variation and the resulting activation requirements
of PKC familymembers, these have been categorized into three
subclasses: The classical PKCs (, I, II, and ) are calcium-
dependent and diacylglycerol and phorbol ester-responsive;
novel PKCs (, , , and ) lack the C2 domain and thus are
calcium-insensitive but retain responsiveness to diacylglycerol
and phorbol ester; atypical PKCs (, 	, and 
) also lack the C2
domain and do not bind diacylglycerol or phorbol ester/diacyl-
glycerol (reviewed in Ref. 1). Depending on their activation
requirements, subcellular localization, and substrate targets,
the function of the PKC isoforms can be extremely diverse (2).
The ability of PKC activators to induce apoptosis in a wide
range of leukemia-derived cell lines has made them attractive
targets for the development of antileukemic drugs (3). In con-
trast to leukemic cells, activation of a broad range of PKC iso-
forms in T lymphocytes inhibits apoptosis and increases prolif-
eration (4). Currently, this differential response to broad range
PKC activators is not fully understood.
The novel PKC-activating agent ingenol-3-angelate
(PEP005) has been identified as the active component of the sap
of the plant Euphorbia peplus. This sap has been used in tradi-
tionalmedicine to treat skin conditions such as actinic keratosis
(5) and basal cell carcinoma (6). PEP005 has been shown to
activate a broad range of PKC isoforms and binds to the C1
domain of classical and novel PKC isoforms (7). More recently,
it has been shown to induce apoptosis in a range of myeloid
leukemia cell lines and in primary human acute myeloid leuke-
mia cells (8) at concentrations in the low nanomolar range. The
outcome of PKC activation depends on several factors, includ-
ing the isoforms expressed and activated in a particular cell,
their direction of translocation upon activation (dictating their
substrate pool) and their down-regulation by proteasomal deg-
radation (1). The proapoptotic effect of PEP005 on leukemia
cells depends on the activation of PKC (8). In contrast, treat-
ment of T cells with broad range activators results in their pro-
liferation and survival. Expression of PKC is widespread, but T
cells also express PKC, an isoform that is present at high levels
only in T cells andmyocytes (9). PKC is highly homologous to
PKC, but the biological functions of these two isoforms differ
considerably. While activation of PKC is commonly associ-
ated with proapoptotic effects (10), the outcome of PKC acti-
vation is generally antiapoptotic (11). Studies using PKC-de-
ficient mice have demonstrated that PKC is an essential factor
for the survival of activated primary T cells (11). PKC is a link
in the chain of signals leading from T cell receptor (TCR) liga-
tion to the activation of NFB, an important regulator of T cell
survival. PKC translocates to the site of contact with the anti-
gen presenting cell, the immunological synapse (12, 13), and
interacts with signalosome constituents, including CARMA1
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(caspase recruitment domain membrane associated guanylate
kinase 1), Bcl-10 (B cell lymphoma 10) and MALT 1 (mucosa-
associated lymphoid tissue 1), aswell as the IBkinase complex.
Within this complex, PKC phosphorylates CARMA1 (14) and
is required to initiate NFB activation (15, 16).
T cell survival is largely regulated by the availability of anti-
apoptotic factors. These survival factors exert their function
through the regulation of expression and subcellular localiza-
tion of pro and antiapoptotic members of the Bcl-2 family.
Among these, particularly in T cells, Bim exerts its proapo-
ptotic effect while antiapoptotic Bcl-2, Mcl-1, and Bcl-xL act as
its counterparts (17, 18).
In the present study, we demonstrate the antiapoptotic effect
of the broad range PKC activator PEP005 on activated and rest-
ing T cells. This activity contrasts with the proapoptotic
response induced inmyeloid leukemic cells. The data show that
PEP005 induced survival of T cells and that this was dependent
on activation of PKC and correlated with up-regulation of
Mcl-1 and Bcl-xL. Furthermore, our work emphasizes the role
of PKC in the divergent response of primary CD8 T cells and
myeloid leukemic cells to PKC activation.
EXPERIMENTAL PROCEDURES
Antibodies and Pharmacological Inhibitors and Activators—
Antibodies used in isolation of CD8 T cells by negative selec-
tion were mouse IgG-specific for CD4 (clone RFT4; Royal Free
Hospital, London, UK), CD11b (OKM1), CD11c (BU15), CD19
(BU12; University of Birmingham), CD14 (UCHM1), CD16
(3G8), TCR (IMMU510) (Beckman Coulter, High
Wycombe, UK), and glycophorin A (GA-R2; BD Biosciences,
Oxford, UK). Antibodies used in multiparameter cell sorting
included CD8-PE (MEM-31, ImmunoTool), CD45RA-PECy5
(MEM56, Serotec), and CCR7-FITC (R&D Systems, Abingdon,
UK). Mouse anti-CD95 antibody (CH11, Upstate) was used to
induce apoptosis in Jurkat T cells. Goat polyclonal -human
IL-2 was used to neutralize IL-2 (Abcam, Cambridge, UK).
PEP005 was supplied by Peplin, Inc., (Brisbane, Australia).
Bisindolylmaleimide I (BisI), Gö6976, 3-(1-(3-imidazol-1-yl-
propyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione, and
myristoylated pseudosubstrate peptide inhibitor of PKC were
used to inhibit PKC, classical PKC isoforms, PKC, and PKC,
respectively (all from Calbiochem, Nottingham, UK). BAY11-
7085 was used to inhibit NFB (Alexis Biochemicals, Notting-
ham, UK).
Cell Isolation and Culture—Peripheral blood mononuclear
cells were isolated by gradient centrifugation using Ficoll-
Paque (Amersham Biosciences, Buckinghamshire, UK). CD8
T cells were isolated by negative selection using antibodies spe-
cific for CD4, CD11b, CD11c, CD19, CD14, CD16, TCR, and
glycophorin A. Goat anti-mouse IgG antibody-coated MACS
microbeads and MACS LS columns were used to remove
labeled cells (Miltenyi Biotech). The remaining CD8 T cells
routinely were96% pure. CD8 T cells were cultured in com-
plete medium (RPMI 1648; Sigma-Aldrich) with 10% v/v heat-
inactivated fetal calf serum (Biosera), 100 g/ml streptomycin,
60 g/ml pencillin, 2 mM L-glutamine, and 10 mM HEPES (all
from Sigma-Aldrich)) containing 50 units/ml IL-2 (Proleukin),
5  104/ml gamma-irradiated Epstein-Barr virus-transformed
lymphoblastoid cells, and 9g/ml phytohemagglutinin (HA15-
PHA, Biostat). Cells were then incubated at 37 °Cwith an atmo-
sphere of 5% CO2 and maintained in complete medium con-
taining 50 units/ml IL-2. Cells were restimulated with the same
protocol weekly and were used for experiments on day 7 after
stimulation. The leukemic cell line NB4 (DSMZ ACC 207) was
purchased from the DSMZ (Braunschweig, Germany). Cells
were maintained in complete medium, RPMI 1640 (Sigma-Al-
drich) supplemented with 10% (v/v) heat-inactivated fetal calf
serum, 100 g/ml streptomycin, 100 units/ml penicillin, 2 mM
L-glutamine, and 10 mM HEPES (all from Sigma-Aldrich), at
37 °C and in a humidified 5% CO2 atmosphere.
Survival and Apoptosis Assays—For assessment of survival,
CD8 T cells were cultured at 1  106 cells/ml in serum-free
medium with RPMI 1640, 2 mM glutamine, 100 units/ml peni-
cillin G, 10 g/ml streptomycin, 10 mM HEPES, 1 mM sodium
pyruvate, 1% (v/v) nonessential amino acids, 52.5 g/ml
leucine, ITS3 medium supplement (10 g/ml insulin, 5.5
g/ml transferrin, 5 ng/ml selenium, 0.5 mg/ml bovine serum
albumin, 4.7 g/ml linoleic acid, and 4.7 g/ml oleic acid) (all
from Sigma-Aldrich), in the presence or absence of PEP005.
Jurkat T cells andNB4 cells were cultured at 1 106 cells/ml in
serum-free medium, in the presence of absence of PEP005.
Apoptosis was assessed by flow cytometric detection of acti-
vated caspase-3. Briefly, cells were fixed and permeabilized
using Caltag Fix and Perm kit (Caltag Laboratories, Inc.), and
activated caspase-3 was detected using a rabbit antibody spe-
cific for the active caspase-3 (BDBiosciences) and revealedwith
an a goat anti-rabbit heavy and light chain fluorescein isothio-
cyanate-conjugated secondary antibody (Southern Biotechnol-
ogy Associates, Inc.).
Simultaneous Detection of Proliferation and Apoptosis—
CD8 T cells were cultured as described above for survival
assays with or without PEP005 at 20 nM. At 24 h from the start
of each experiment, cells were pulsed with 10 M of bromode-
oxyuridine (BrdUrd, BD Biosciences) for 2 h in dark at 37 °C.
Cells were then washed twice in culture medium and resus-
pended in 200 l of serum-free medium with and without
PEP005 corresponding to their original culture conditions. At
48 h, cells were resuspended and washed once in PBS and
stained for BrdUrd and active caspase-3 using the BD BrdUrd
flow kit (BD Biosciences). Briefly, cells were resuspended in 50
l Cytofix/Cytoperm buffer and incubated at room tempera-
ture for 20 min, followed by one washing step using 200 l of
1 Perm/Wash buffer. Cells were then resuspended in 50 l of
Cytoperm plus buffer and incubated on ice for 10 min before
incubationwith 50l of Cytofix/Cytopermbuffer at room tem-
perature for 20min, followed by one washing step. Each sample
of cells was resuspended in 30l of 30g/l DNase I plus 20l
PBS and incubated at 37 °C for 1 h. Cell were washed once in
200 l of 1 Perm/Wash buffer and then resuspended in 50 l
of 1 Perm/Wash buffer plus 10 l of diluted mouse anti-
BrdUrd-APC (allophycocyanin) and rabbit antiactive caspase-3
monoclonal antibody in 1 Perm/Wash buffer. Cells were
incubated in the dark at room temperature for 20 min fol-
lowed by one washing step. Cells were then resuspended in
50 l of goat anti-rabbit heavy and light chain fluorescein
isothiocyanate secondary antibody in 2% bovine serum albu-
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min/PBS and incubated in the dark at room temperature for
30 min before washing and analysis on a FACSCaliburTM
flow cytometer (BD Biosciences).
Isolation of Human CD8 T Cell Subsets by Multiparameter
Cell Sorting and Survival Assays—CD8 T cell subpopulations
were purified by multiparameter cell sorting on a Coulter
MoFloTM cell sorter. Cells expressing a high level of CD8 were
chosen for further gating for isolation of different CD8 T cell
subsets. Four subsets of CD8 T cells, namely, naïve, central
memory, effector memory and CD45RA-expressing effector
memory cells were isolated by their corresponding phenotypes
identified by expression of CD45RA and CCR7. Purity of the
sorted cells routinely was 95%. Harvested subpopulations
were cultured in serum-free medium at 1  106 cells/ml and in
the presence/absence of 20 nM PEP005. On day 7, the percent-
age of apoptosis was analyzed by flow cytometry for active
caspase-3.
Western Blotting—2  105 T cells were lysed in SDS-PAGE
sample buffer, and total cellular proteins were separated by
SDS-PAGE and transferred to polyvinylidene difluoride mem-
brane (Geneflow, Fradley, UK). Blots were blocked in 5% (w/v)
nonfat milk powder and 0.1% (v/v) Tween 20 in Tris-buffered
saline (10 mM Tris, pH 7.5, 150 mM NaCl). Primary antibodies
used were mouse anti-Bcl-xL (2H12, BD Pharmingen, Oxford,
UK), rat anti-Bim (14A8, Calbiochem,Nottingham,UK), rabbit
anti-Mcl-1 (S-19, Santa Cruz Biotechnology, Inc., Heidelberg,
Germany), mouse anti-PKC (R&D Systems), and -actin
(AC74, Sigma). Horseradish peroxidase-linked sheep anti-
mouse IgG, donkey anti-rabbit IgG, and goat anti-rat IgG were
used as secondary antibodies.
Immunoprecipitation of Activated PKC—15 106 activated
CD8 T cells were were first treated either with or without 10
Mmyristoylated pseudosubstrate peptide inhibitor of PKC at
37 °C for 30 min and then either with or without 20 nM PEP005
at 37 °C for 15min. Cells werewashed twice in ice-cold PBS and
resuspended in 1 ml of lysis buffer (5 mM sodium orthovana-
date, 5mM sodiumpyrophosphate, 5mM sodium fluoride, 5mM
EDTA, 50 mM sodium chloride, 2% (v/v) Igepal, 50 mMHEPES,
pH 7.4, protease inhibitor mixture, which contains 1.04 mM
4-(2-aminoethyl)benzenesulphonyl fluoride chloride (AEBSF),
800 nM aprotinin, 20 M leupeptin, 40 M bestatin, 15 M pep-
statin A, and 14 M E-64) and incubated on ice for 30 min. Cell
debris was removed by centrifugation for 10 min at 10,000  g
at 4 °C. Cell lysates were then incubated with 5 l of rabbit
polyclonal pThr-219 PKC antibody raised against phospho-
threonine-containing peptide sequence, NH2-INSREpThr-
219MFHKE-COOH, coupled to keyhole limpet hemocyanin
(KLH) (kind gift from Dr. Gottfried Baier, Innsbruck Medical
University), overnight at 4 °C. Protein Gmicrobead suspension
(Miltenyi Biotec, Surrey, UK) was used to label the immune
complex at 4 °C for 1 h. pThr-219PKC-specific immunocom-
plexes were isolated by separation columns attached to a
MACS separator (both from Miltenyi Biotec, Surrey, UK)
with fourwashes of lysis buffer and onewash of 20mMTrisHCl,
pH 7.5 and eluted with hot (95 °C) SDS loading buffer.
Unbound cell lysate was mixed with 0.2 volumes of 5-fold con-
centrated SDS loading buffer and kept for analysis of -actin as
a control for equal cell input.
Transfection of CD8 T Cells with Kinase-inactive PKC—
CD8 T cells were isolated by negative selection using a CD8
T cell isolation kit from Miltenyi Biotech. The isolated cells
were routinely 95% CD8 T cells and were transfected using
the AMAXA T cell transfection kit. Briefly, 2  106 cells were
resuspended in 100 l of nucleofector solution V and mixed
with 1 g of pmaxGFP and 5 g of pEFPKCK/R (19). Cells
were electroporated with a Nucleofector II device (Lonza, Ger-
many) using programU-014. 500 l of prewarmed transfection
culture medium (RPMI 1640 supplemented with 2 mM L-gluta-
mine, 10 mMHEPES, 10% (v/v) fetal calf serum and adjusted to
4.5g/liters glucose) was added to cells and transferred to 1.5 ml
prewarmed culture medium. Transfected cells were incubated
at 37 °C, 5% CO2 for 6 h and then incubated in complete
medium for 24 h in the presence or absence of 20 nM PEP005.
Levels of apoptosis were assessed by staining for active
caspase-3 as described above. A phycoerythrin-labeled second-
ary goat anti-rabbit antibody was used for detection. For anal-
ysis of transfected cells, GFP-expressing cells were selected.
Transfection of NB4 Cells with PKC—An empty plas-
mid (pEFneo) and a plasmid encoding wild-type PKC
(pEFwtPKCneo)were kind gifts fromDr.GottfriedBaier (Uni-
versity of Innsbruck). pmaxGFP (0.5 g/l) is provided in the
Cell Line Nucleofector Kit V to monitor transfection efficiency
and cell sorting of transfected cells. Transfection was per-
formed using the Cell Line Nucleofector Kit V (Lonza). Briefly,
2  106 cells were resuspended in 100 l Nucleofector solution
V and mixed with 1 g pmaxGFP and either 1.5 g pEFneo or
pEFwtPKCneo. Cells were electroporated with aNucleofector
II device (Lonza) using the program X-001. 500 l of pre-
warmed transfection culture medium (RPMI 1640 supple-
mented with 2 mM L-glutamine, 10 mM HEPES, and 10% (v/v)
fetal calf serum and adjusted to 4.5 g/liters glucose) was added
to cells and transferred to 1.5ml of prewarmed culturemedium.
Transfected cells were incubated at 37 °C, 5%CO2 for 6 h. GFP-
positive transfected cells were isolated using a MoFloTM cell
sorter (Beckman Coulter) with a purity of 97% and then incu-
bated in complete medium for 10 h in the presence or absence
of 20 nM PEP005. Levels of apoptosis were assessed by staining
for active caspase-3.
Detection of NFB (p65) Activation—CD8 T cells were
treated in the conditions stated, and nuclear extracts were
obtained with a commercial kit (Active Motif). Briefly, cells
were washed twice in PBS-based phosphatase inhibitor buffer
(PBS/PIB; 6.25 mM sodium fluoride, 12.5 mM -glycerophos-
phate, 12.5 mM para-nitrophenyl-phosphate, and 1.25 mM
sodium vanadate and then resuspended in hypotonic buffer (20
mM HEPES, pH 7.5, 5 mM sodium fluoride, 10 M sodium
molybdate, and 0.1 mM EDTA) at 56.8 l/106 cells and incu-
bated on ice for 15 min. Nonidet P-40 was added to a final
concentration of 0.5% (v/v), and samples were mixed. Nuclear
fractions were harvested by centrifugation at 14,000  g at 4 °C
for 30 s. Nuclear pellets were resuspended in lysis buffer (5 mM
dithiothreitol, protease inhibitormixture, and lysis bufferAM2,
supplied in kit) at 5.68l/106cells and agitated on ice at 150 rpm
for 30min.Nuclear extractswere harvested after centrifugation
at 14,000  g at 4 °C for 10 min. Protein concentration of
nuclear extracts was determined by BCATM protein quantifica-
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tion kit (Perbio Science, Cramlington, UK). Activated p65 was
quantified using theTransAMp65 activation kit (ActiveMotif).
Briefly, 10 g of nuclear extract was plated on microwells
coated with DNA oligonucleotides containing activated p65
consensus binding elements. After binding and washing, an
antibody specific for DNA-bound p65 was added. An anti-rab-
bit IgG horseradish peroxidase antibody was used for signal
detection and quantification.
Immunofluorescence and Quantification of p65 in CD8 T
Cells—2  106/ml CD8 T cells in serum-free medium were
first treated with or without 10 M myristoylated pseudosub-
strate peptide inhibitor of PKC at 37 °C for 30 min and then
with or without 20 nM PEP005 for 15 min. Cells were trans-
ferred to glass slides in a cytocentrifuge (Shandon). Cells were
fixed in 4% formaldehyde in PBS (v/v) at room temperature and
permeabilized in absolute methanol at 20 °C. Blocking was
performed with 10% horse serum (v/v) in PBS for 1 h. Mono-
clonal rabbit anti-p65 (clone C22B4, Cell Signaling) diluted in
1% bovine serum albumin/PBS (w/v) was applied for 1 h fol-
lowed by three washes with PBS. TRITC-conjugated donkey
anti-rabbit IgG (Jackson ImmunoResearch Laboratories) was
applied for 1 h followed by threewashes in PBS. The nuclei were
counterstained with Hoechst 33258 at 20 g/ml. Images were
acquired using a confocal immunofluorescence microscope
(Zeiss LSM510 based on a Zeiss AxiophotM100). Contrast and
brightness were enhanced using
Zeiss LSM software. Mean pixels
per m2 of total p65 staining and
p65 staining co-localized with
Hoechst in unprocessed images of
10 cells for each slide were quanti-
fied using the LSM 510 software
(Zeiss).
Statistical Analysis—Data pre-
sented here represent aminimumof
three experiments and, where
appropriate, data are expressed as
mean  S.D. Statistical significance
was assessed by paired two-tail Stu-
dent’s t test, and p  0.05 was taken
as a significantly different value.
Multiple comparisons were ana-
lyzed for statistical significance by
one and two-way analysis of vari-
ance, as appropriate. An asterisk
denotes p  0.05, whereas ns
denotes p  0.05.
RESULTS
The plant-derived PKC activator
PEP005 initiates apoptosis in a
range of cell lines derived frommye-
loid leukemia, including NB4, as
well as primary leukemic cells from
patients with acute myeloid leuke-
mia (8). As shown in Fig. 1a, we con-
firm that apoptosis is triggered in
NB4 cells at nanomolar concen-
trations of PEP005. In contrast, PEP005 did not affect the sur-
vival of Jurkat cells (Fig. 1b), a human T cell leukemia cell line
(20). Activated human T cells enter apoptosis spontaneously if
deprived of survival factors such as IL-15 or IL-2. This sponta-
neous entry into the apoptotic pathway can be inhibited by
PEP005 (Fig. 1c) in normal activated human T cells. In the
experiment shown in Fig. 1c, activated CD8 T cells were
exposed to PEP005 in the absence and presence of 25 units/ml
IL-2. The same concentrations of PEP005 that induced apopto-
sis in NB4 cells significantly inhibited apoptosis of IL-2
deprived CD8 T cells. Survival of activated CD4 T cells was
affected to a similar extent, in the presence of fetal calf serum
apoptosis was delayed, but the antiapoptotic effect of PEP005
was not affected (data not shown). Time course experiments
shown in Fig. 1d revealed that this is not a permanent block of
apoptosis but rather a delay of apoptosis to the same extent as
addition of optimal concentrations of IL-2. Detection of an
epitope specific for activated caspase 3was used as a readout for
apoptosis.Mitochondrial depolarizationwas assessed by detec-
tion of JC-1 incorporation in parallel experiments, yielding con-
sistent results (data not shown).
The effects of manymodulators of apoptosis are restricted to
cells in the active phases of the cell cycle (21). Therefore, we
tested whether the effect of PEP005 was restricted to prolifer-
ating T cells. For this purpose, an assay was developed to dis-
FIGURE 1. PEP005 induces apoptosis in NB4 cells and does not affect survival of Jurkat cells but inhibits
apoptosis of activated CD8 T cells. NB4 (A) and Jurkat T (B) cells were treated with indicated concentrations
of PEP005, and levels of apoptosis were analyzed by intracellular staining of active caspase-3 on day 2. C, acti-
vated CD8 T cells were treated in the presence (empty bars) and absence of 25 units/ml IL-2 (filled bars) and/or
indicated concentrations of PEP005. Levels of apoptosis were analyzed by intracellular staining of active
caspase-3 on day 2. D, survival assays were set up similarly to C with an extended time course to day 7. dashed
line and filled squares, untreated cells; dashed line and empty squares, cells treated with 25 units/ml IL-2, solid line
and empty triangles, cells treated with 20 nM PEP005 with 25 units/ml IL-2; and solid line and filled triangles, cells
treated with 20 nM PEP005 without 25 units/ml IL-2. E, simultaneous detection of proliferation and apoptosis by
BrdUrd/caspase-3 double staining shows no difference between the effect of PEP005 on proliferating cells
compared with nonproliferating cells. CD8 T cells were cultured as described above for survival assays with
and without 25 units/ml IL-2 and/or 20 nM PEP005. At 24 h from the start of each experiment, cells were pulsed
with BrdUrd for 2 h. At 48 h, cells were labeled with antibodies to BrdUrd and activated caspase-3. BrdUrd-
positive and -negative cells were gated, and the percentage of cells with activated caspase-3 is shown in E. Data
are mean  S.D. from four separate experiments. An asterisk denotes p  0.05, whereas ns denotes p  0.05.
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tinguish between cells that had been actively proliferating dur-
ing a 2-h time window in which the cells were exposed to
BrdUrd. At the end of a 48-h incubation period, the cells were
stained for active caspase-3 and for incorporation of BrdUrd.
As shown in Fig. 1e, PEP005 inhibited apoptosis both in T cells
that had been actively proliferating during the BrdUrd expo-
sure and cells that had not been in S-phase. We conclude from
these experiments that PEP005 does not preferentially affect
proliferating T cells.
Although the initial experiments focused on the effects of
PEP005 on in vitro-activated CD8 T cells, the next series of
experiments was directed at the effects of PEP005 on freshly
isolated resting human CD8 T cells. Depending on the
parameters used, these cells can be subdivided into a number
of functionally distinct subpopu-
lations (22). Co-labeling with anti-
bodies detecting CCR7 and CD45RA
allows distinction of four subsets:
naïve CD8 T cells coexpressing
CCR7 and CD45RA, central memory
T cells expressing CCR7 but not
CD45RA, effector memory T cells
negative for both CCR7 and
CD45RA, and a smaller subset of T
cells expressing CD45RA but not
CCR7 (Fig. 2). Sorting and culturing
these cells in the presence and
absence of PEP005 showed that
althoughnaïve and centralmemoryT
cells had a significant increase in their
survival, there was no significant
change in the apoptosis of effector
memory or CCR7CD45RACD8
T cells.
T cells stimulated to produce IL-2
can extend their own survival and
proliferation by an autocrine loop
(23). To test whether such an auto-
crine loop was mediating the anti-
apoptotic effect of PEP005 on T
cells, a blocking antibody to IL-2
was added to the cultures. As shown
in Fig. 3a, whereas the blocking
antibody could eliminate the effect
of externally added IL-2, it did not
inhibit PEP005-mediated survival of
T cells. These observations suggest
that the inhibition of T cell death
cannot be explained by PEP005-in-
duced IL-2 production.
PEP005 can activate a broad
range of PKC isoforms; many of
these can up- or down-regulate the
rate of apoptosis. To test whether
the antiapoptotic effect of PEP005
was dependent on the activation of
PKC, BisI, a PKC inhibitor with
broad specificity for classical and
novel PKC isoforms was added to the cultures. As shown in Fig.
3b, BisI can completely abrogate the survival effect of PEP005.
The inhibitor of classical PKC isoforms Gö6976, on the other
hand, only had a partial effect on the PEP005-mediated inhibi-
tion of T cell apoptosis (Fig. 3c). An inhibitor specific for PKC
did not have a significant effect on the inhibition of T cell apo-
ptosis mediated by PEP005 (Fig. 3d). This observation sug-
gested an involvement of novel PKC isoforms in the antiapop-
totic effect of PEP005.
Among the novel PKC isoforms, PKC is an important reg-
ulator of T cell survival. As described previously, PKC is not
expressed inmyeloid cells (9). Titration of varying cell numbers
of NB4 and activated CD8 T cells into Western blots con-
firmed the reports that PKC is expressed by T cells but not by
FIGURE 2. PEP005 inhibits apoptosis in resting peripheral blood naive and effector memory CD8 T cells
ex vivo. Resting human peripheral blood CD8 T cells were sorted according to their expression of CD45RA
and CCR7. Ex vivo sorted CD8 T cells were cultured in serum-free medium in the presence/absence (-ve) of
PEP005, and levels of apoptosis were analyzed by intracellular staining of active caspase-3 on day 7. Data show
mean of a minimum of three separate experiments. TCM, central memory; TEM, effector memory; TEMRA, CD45RA-
expressing effector memory. An asterisk denotes p  0.05, whereas ns denotes p  0.05.
FIGURE 3. Antiapoptotic effect of PEP005 requires PKC activation and is not dependent on autocrine IL-2
production. Activated CD8 T cells were treated in the presence/absence of an anti-IL-2 antibody (A), indi-
cated concentrations of pan-PKC inhibitor BisI (B), cPKC inhibitor (inhib.) Gö6976 (C), PKC-specific inhibitor (D)
and 25 units/ml IL-2 and/or 20 nM PEP005 for 2 days. Levels of apoptosis were analyzed by intracellular staining
of active caspase-3. Although the survival effect depends on PKC activation, inhibition of classical PKC by
Gö6976 only had a partial effect, and inhibition of PKC did not reduce significantly the antiapoptotic effect of
PEP005. Data are mean  S.D. from three separate experiments. An asterisk denotes p  0.05, whereas ns
denotes p  0.05.
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NB4 cells (Fig. 4a). Positive evidence for activation of PKC by
PEP005 was yielded by experiments involving immunoprecipi-
tation of PKC phosphorylated on Thr-219, a site associated
with enzymatic activity (Fig. 4b). Although the phosphorylation
of PKC at Thr-219 was induced by PEP005, it could be inhib-
ited by the PKC-specific inhibitor.We therefore hypothesized
that PKC expression by T cells may explain the observation
that broad range PKCactivation leads to an antiapoptotic signal
in T cells while it induces apoptosis in myeloid leukemia cell
lines. In the next series of experiments, we used a specific pep-
tide inhibitor of PKC. As shown in Fig. 4c, inhibition of PKC
could completely abrogate the survival effect of PEP005 on T
cells. In contrast, the antileukemic effect of PEP005 on leuke-
mia cells was not affected by the
PKC inhibitor (Fig. 4d). This result
suggests that the inhibition of PKC
does not affect the proapoptotic
effect mediated by PKC, which is
highly homologous to PKC (24)
and allows separation of the pro-
apoptotic effect of PEP005 on leuke-
mic cells from the antiapoptotic
effect on T cells. Transfection of
peripheral blood CD8 T cells with
a dominant-negative, kinase-inac-
tive mutant of PKC significantly
reduced the antiapoptotic effect of
PEP005 (Fig. 4, e–g). As expected
for a kinase involved in the inhibi-
tion of apoptosis, transfection
with a dominant-negative form of
PKC also increased the amount
of constitutive apoptosis (Fig. 4f).
We further confirmed the role of
PKC in the inhibition of apopto-
sis by transfection of NB4 cells
with a plasmid coding for full-
length PKC (Fig. 4h). Whereas
PEP005 treatment increased apo-
ptosis in NB4 cells transfected
with empty control vector, the
PKC-transfected cells responded
to PEP005 with inhibition of apo-
ptosis (Fig. 4i). Due to the techni-
cal difficulty of transfecting pro-
myelocytic cells without inducing apoptosis, the differences
observed were not very dramatic; however, the observed effect
was highly reproducible. These data support the contention that
expression of PKC determines whether a hematopoietic cell
receives a pro- or antiapoptotic stimulus when exposed to broad
range PKC-activating agents.
In a further series of experiments, the molecular mechanism
causing the antiapoptotic signal induced by PEP005 was inves-
tigated. The relative levels of expression of Bcl-2 family mem-
bers govern the decision between survival and apoptosis in
many aspects of T cell biology (18). The expression of the pro-
apoptotic protein Bim is thought to initiate mitochondrial
FIGURE 4. Role of PKC in the response of NB4 cells and T cells to PEP005. A, expression of PKC in NB4 cells and CD8 T cells was determined by Western
blotting of cell lysate obtained from 1, 2, and 4  105 cells with an anti-PKC antibody. B, activation of PKC upon PEP005 exposure was detected by
immunoprecipitation of activated PKC phosphorylated at threonine 219 and detection of PKC by Western blotting. Phosphorylation of PKC was blocked by
preincubation of the cells with PKC inhibitor (PKC inhib.) Detection of -actin in the unbound lysate was used to control for equivalent cell input. C, activated
CD8 T cells were preincubated with (triangles) and without (squares) 10 M PKC inhibitor and then with indicated concentrations of PEP005 in the absence
of IL-2. Levels of apoptosis were analyzed by intracellular staining of active caspase-3 on day 2. D, NB4 cells were cultured in the presence and absence of 10 M
PKC inhibitor in the presence/absence of 20 nM PEP005. Levels of apoptosis were analyzed on day 2 by detection of activated caspase 3. E, peripheral blood
CD8 T cells were transfected with an expression vector coding for kinase-inactive PKC (PKCK/R). Western blots of cell lysates of control transfected or
kinase-inactive PKC-transfected cells were probed with an anti-PKC antibody. F, after 6 h of transfection, control and PKCK/R transfected CD8 T cells were
incubated in the presence or absence of PEP005 for 24 h. The percentage of apoptotic cells was determined by staining for activated caspase-3 and gating on
the GFP expressing cell population. G, the percentage of apoptotic cells in PEP005-treated cells from three independent experiments on CD8 T cells
transfected with GFP and kinase-inactive PKC is shown. H, PKC expression was detected in GFP-sorted NB4 cells co-transfected with empty vector or
PKC-coding vector. I, GFP-sorted NB4 cells co-transfected with PKC-coding (black bar) and control vector (empty bar) were treated with 20 nM PEP005 for
10 h, and apoptosis was detected by intracellular staining of active caspase-3. Data shown are for PEP005-treated cells and are expressed as mean  S.D. for the
percent increase or decrease of apoptosis over untreated cells. Data shown are mean  S.D. from a minimum of three independent experiments. An asterisk
denotes p  0.05, double asterisks denote p  0.01, whereas ns denotes p  0.05.
FIGURE 5. Induction of Mcl-1 and Bcl-xL and reduction of BimEL in activated CD8
 T cells by PEP005. A, 1 
106/ml activated CD8 T cells in serum-free medium were treated in the presence/absence of 300 nM BisI or 10
M PKC inhibitor (inhib.) for 30 min and then in the presence/absence of 20 nM PEP005 for the duration
indicated. Cell lysates were analyzed by immunoblotting with antibodies specific for Bcl-2, Mcl-1, Bcl-xL, and
Bim; -actin was measured as a loading control. B, abundance of Mcl-1, Bcl-xL, and BimEL in cell lysates were
quantified by densitometry of immunobands. Density of immunobands were first normalized to that of -actin
and then normalized to values of untreated cells of 15 min in culture (Mcl-1 and Bcl-xL) or untreated cells of 24 h
in culture (BimEL). Data shown are mean  S.D. from five separate experiments. An asterisk denotes p  0.05,
whereas ns denotes p  0.05.
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depolarisation in T cells, which can be counterbalanced by
expression of Bcl-2, Bcl-xL, orMcl-1. The levels of expression of
these proteins were investigated in T cells treated either for 15
min or for 24 hwith PEP005. As shown in Fig. 5, PEP005 did not
lead to any obvious changes in Bcl-2 levels. However, within
24 h, an increase of Mcl-1 and Bcl-xL levels was observed. The
level of expression of BimEL, the highest molecular weight iso-
form of Bim, increased at 24 h. The increase in BIMEL was
dramatically reduced in the presence of PEP005. In cells treated
with PEP005, we also observed appearance of a higher molecu-
lar weight band. This band may correspond to the phosphory-
lated form of BimEL. The addition of either BisI, or the PKC
inhibitor, prevented the increase in expression of Mcl-1 and
Bcl-xL. The reduced levels of BimEL expression in cells cultured
with PEP005 were not affected by inhibition of PKC or PKC.
The lower levels of BimEL may
either be caused by an inhibition of
the increase in BimEL levels or by
accelerated PKC-independent deg-
radation. We conclude from our
investigation of the effect of PEP005
on relative levels of Bcl-2 family
members, that PKC activation by
PEP005 increases cell survival by
alteration of the balance between
pro- and antiapoptotic members of
the Bcl-2 family.
Expression of Mcl-1 as well as
Bcl-xL is regulated by the canonical
NFB pathway; an important regu-
lator of cell survival that is a known
target for PKC.The effect of PEP005
on the activity of NFB p65 was
assayed by a plate-bound assay of
nuclear translocation of p65 (Fig. 6,
a and b). PEP005 treatment led to
rapid nuclear translocation of p65.
This activation was blocked entirely
by the PKC inhibitor. We further
confirmed these observations by
staining cytospin preparations of
activated CD8 T cells with anti-
NFB p65 antibody. Cells were
treated either with or without
PEP005 after pretreatment with or
without PKC  inhibitor (Fig. 6c).
Nuclear translocation was quanti-
fied and showed a significant in-
crease in the nuclear p65 level that
was inhibited in the cells pretreated
with the PKC inhibitor (Fig. 6d).
Inhibition of NFB activity led to
a titratable increase of the rate of
spontaneous apoptosis. The anti-
apoptotic effect of PEP005 was sig-
nificantly reduced by addition of
BAY11-7085 (Fig. 6e). Taken
together, these data suggest that
PEP005 treatment-induced PKC activation leads to nuclear
translocation of NFB p65 and that the antiapoptotic effect
depends on NFB activation.
DISCUSSION
The observations made in this study provide an explana-
tion for the difference in the response of myeloid leukemia
cell lines and T cells to PKC activation. Whereas many cell
lines enter apoptosis upon treatment with PEP005, T cells
receive a strong antiapoptotic signal. The data shown here
indicate that this antiapoptotic signal is mediated by activa-
tion of PKC in T cells. Downstream of PKC activation, we
observed activation of the canonical NFB pathway and a
change in the ratio between expression of proapoptotic Bcl-2
family member BimEL and antiapoptotic family members
FIGURE 6. Activation of NFB by PEP005 inhibits apoptosis of activated CD8 T cells. A, activated CD8
T cells were treated in the presence/absence of 10 M PKC inhibitor (inhib.) and then in the presence/
absence of 20 nM PEP005 for 5, 10, and 15 min. Nuclear extracts were analyzed for activated p65 with the
TransAM NFB p65 activation kit. A, data shown are mean  S.D. of the corrected absorbance (A450 nm–
A650 nm). B, fold increase values were obtained by normalization of absorbance values from untreated
cells. C, immunofluorescence staining for p65 on activated CD8 T cells treated for 15 min with 20 nM
PEP005 with and without pretreatment with PKC inhibitor. D, the percentage of p65 in the nuclei of
activated CD8 T cells treated as detailed above. Data shown are mean  S.D. of the nuclear p65 expres-
sion detected as a percentage of the total cellular level of p65. E, activated CD8 T cells were treated in the
presence/absence of indicated concentration of BAY11-7085 prior to addition of 25 units/ml IL-2 or 20 nM
PEP005. Levels of apoptosis were analyzed by intracellular staining of active caspase-3 on day 2. Data are
mean  S.D. from five independent experiments. An asterisk denotes p  0.05, whereas ns denotes p 
0.05.
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Bcl-xL and Mcl-1. Most cytotoxic drugs used in chemo-
therapy target rapidly proliferating cells and therefore sup-
press the function of the immune system. PKC activators,
however, induce apoptosis in many myeloid leukemia cell
types in vivo and in vitro and at the same time act as potential
immune stimulants. They were shown to cause T cell activa-
tion, proliferation, and secretion of cytokine such as IL-2 (4).
Previous work from our group has shown that nanomolar
concentrations of PEP005 triggered apoptosis of cells lines
derived from patients with acute myeloid leukemia (8), and,
in the other independent study, PEP005 enhanced cytotoxic
functions of neutrophils in vitro and prevented relapse of
grafted skin tumors in vivo (25). The only previous study of
effects of PEP005 on T cells was investigating the cytokine
production by T cells of acute myeloid leukemia patients in
vitro. If added in conjunction with stimulating anti-CD3
antibody, PEP005 increased cytokine release (including IL-2
and interferon-) from T cells (26). The previous finding
that PEP005 can increase IL-2 production raised the possi-
bility that the underlying survival mechanism in T cells was
an autocrine loop of increased IL-2 production. Inhibition
with blocking anti-IL-2 antibodies, however, did not prevent
the antiapoptotic effect of PEP005 on T cells. Looking for an
alternative mechanism, we investigated the effect of PEP005
on PKC. The essential role of PKC signaling for activation
of NFB in T cell activation and survival is well established
(15, 16). Our own studies on survival of activated CD8 T
cells have indeed shown that PEP005 activates PKC. Phos-
phorylation of Thr-219, an autophosphorylation site critical
for NFB activation, was clearly demonstrated (27). The
NFB pathway is an important regulator of the balance
between pro- and antiapoptotic Bcl-2 family proteins. These
regulate CD8 T cell apoptosis at different development and
differentiation stages; it has been shown that cytokine-dep-
rivation mediated apoptosis of activated CD8 T cells and
viral antigen-specific CD8 T cells from patients with
chronic viral infection were caused by loss of Mcl-1 and
increased expression of BimEL (28, 29). On the other hand,
Bcl-xL up-regulation mediated by T cell activation and
PKC-NFB signaling supports survival of activated T cells
(11, 30, 31). The ability to express these antiapoptotic Bcl-2
members autonomously can enhance the lifespan of effector
T cells. That regulation Bcl-2 itself was not observed in our
system may be due the larger nonregulated nuclear pool of
Bcl-2, which can mask regulation of the mitochondrial level
of Bcl-2 (32). Our finding recapitulates the role of antiapo-
ptotic Bcl-2 members in CD8 T cell apoptosis, as the loss of
Mcl-1 and elevated BimEL expression followed by cytokine
deprivation was reversed by PEP005, together with the up-
regulation of Bcl-xL. When PKC was inhibited, PEP005-
induced activation of NFB was completely abrogated, and
this, together with the failure of Mcl-1 and Bcl-xL up-regu-
lation, subsequently led to activation of caspase-3 and
apoptosis.
Homeostatic control of naïve CD8 T cell numbers is
highly regulated by levels of common -chain cytokines IL-7
and IL-15 and stimulation of MHC-I molecules (33). Follow-
ing antigen clearance, declined availability of survival factors
renders activated CD8 T cells highly susceptible to apopto-
sis. PEP005 inhibited this cytokine-deprivation induced apo-
ptosis by delaying the process of apoptosis of freshly isolated
naïve and also central memory CD8 T cells in vitro. It is
interesting, in this context, that central memory CD8 T
cells, in particular, were found to be the most effective CD8
T cell subset in generating anti-tumor responses in vivo
(34).
We conclude from these studies, that broad range PKC
activation can be a survival factor for activated and resting T
cells, whereas it exerts a powerful proapoptotic signal to leu-
kemia cells. This divergent response can be explained by the
difference in expression of PKC between T cells and leuke-
mic cells derived from acute myeloid leukemia patients.
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